{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=67",
    "query": {
      "condition": "Hematologic Disease",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 10730,
    "total_pages": 1073,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Disease&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T17:04:55.035Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00498316",
      "title": "Cord Blood Expansion on Mesenchymal Stem Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Cord Blood Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "1 Year to 80 Years"
      },
      "enrollment_count": 98,
      "start_date": "2007-07-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498316"
    },
    {
      "nct_id": "NCT04459416",
      "title": "Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Hodgkin Disease",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Acupuncture",
          "type": "OTHER"
        },
        {
          "name": "opioid",
          "type": "DRUG"
        },
        {
          "name": "Assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 299,
      "start_date": "2020-06-30",
      "completion_date": "2027-06",
      "has_results": true,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 2,
      "location_summary": "New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04459416"
    },
    {
      "nct_id": "NCT01656252",
      "title": "Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Phase I- Cytarabine & Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Phase II- Sequence A",
          "type": "DRUG"
        },
        {
          "name": "Phase II- Sequence B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-07",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2020-11-03",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 5,
      "location_summary": "Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01656252"
    },
    {
      "nct_id": "NCT00015847",
      "title": "Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 25,
      "start_date": "2001-04",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Portland, Oregon",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015847"
    },
    {
      "nct_id": "NCT03399448",
      "title": "NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Melanoma",
        "Synovial Sarcoma",
        "Myxoid/Round Cell Liposarcoma"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 expression testing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2018-09-05",
      "completion_date": "2020-10-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399448"
    },
    {
      "nct_id": "NCT04425655",
      "title": "Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, Adult",
        "AML",
        "AML, Adult"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Vyxeos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-08-05",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-22",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04425655"
    },
    {
      "nct_id": "NCT05831176",
      "title": "A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Gastritis (EoG)",
        "Eosinophilic Duodenitis (EoD)",
        "Eosinophilic Gastrointestinal Disease (EGID)",
        "Eosinophilic Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-05-03",
      "completion_date": "2026-11-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Apple Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831176"
    },
    {
      "nct_id": "NCT03301168",
      "title": "Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Leukemia, Acute Myeloid (AML), Child",
        "Lymphoma, Non-Hodgkin",
        "Myelodysplastic Syndromes",
        "Primary Immune Deficiency Disorder",
        "Osteopetrosis",
        "Cytopenia",
        "Hemoglobinopathy in Children",
        "Anemia, Aplastic"
      ],
      "interventions": [
        {
          "name": "BPX-501 T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "1 Month to 26 Years"
      },
      "enrollment_count": 120,
      "start_date": "2014-04",
      "completion_date": "2034-05",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301168"
    },
    {
      "nct_id": "NCT03907436",
      "title": "The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Myeloproliferative Disorder",
        "Myeloproliferative Syndrome",
        "Myelofibrosis",
        "Polycythemia Vera",
        "Essential Thrombocythemia"
      ],
      "interventions": [
        {
          "name": "USDA Diet",
          "type": "OTHER"
        },
        {
          "name": "Mediterranean Diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-10-01",
      "completion_date": "2019-10-01",
      "has_results": false,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907436"
    },
    {
      "nct_id": "NCT01975844",
      "title": "The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Individualized Anemia Mangement Protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Michael Germain",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2013-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-03-26",
      "last_synced_at": "2026-11-19T17:04:55.035Z",
      "location_count": 1,
      "location_summary": "Chicopee, Massachusetts",
      "locations": [
        {
          "city": "Chicopee",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01975844"
    }
  ]
}